[Perazine-induced agranulocytosis--case report].
This complication normally arises between the 5th and 10th weeks of treatment and is most commonly seen in middle-aged and elderly women. The risk is estimated to be between 0.04% and 2%, depending on the type of medication and the method of assessment. The present report describes a 16-year-old boy who developed agranulocytosis after 4 weeks of treatment with perazine. The problem was complicated by acute toxoplasmosis. After perazine was discontinued the neutrophils recovered within 5 days; the boy did develop fever, but the infectious disease had a mild course. This case report once again confirms the importance of regular blood control during the early phases of treatment with psychopharmacological agents.
D000293:Adolescent; D000380:Agranulocytosis / Q000139:chemically induced*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D006212:Hallucinations / Q000188:drug therapy; D006801:Humans; D008297:Male; D010464:Perazine / Q000009:adverse effects* / Q000627:therapeutic use; D012563:Schizophrenia, Paranoid / Q000188:drug therapy*; D014123:Toxoplasmosis / Q000150:complications
D014150:Antipsychotic Agents; D010464:Perazine
Perazin-induzierte Agranulozytose--Fallbericht.